摘要
目的探讨中晚期肝癌(HCC)患者接受抗甲胎蛋白抗体介导的双弹头导向药物治疗对细胞免疫功能的影响。方法采用碱性磷酸酶 -抗碱性磷酸酶法和51Cr释放试验 ,分别测定了HCC患者T细胞亚群数和NK细胞的活性。结果导向组患者用导向药物治疗后 ,其NK细胞和CD3 +T细胞、CD4 +T细胞数 ,CD4 +/CD8 +T细胞比值均无显著降低 ,CD8 +T细胞数无明显升高(P均>0.05) ;而化疗组患者做化疗后 ,其NK细胞的活性和CD3+ T细胞、CD4 +T细胞数 ,以及CD4 +/CD8 +T细胞的比值均显著降低 ,CD8+ T细胞数显著升高(P均<0.05)。结论该双弹头导向药物对HCC患者的细胞免疫功能无影响 ,而化疗患者的细胞免疫功能则明显下降。
Aim To explore the changes of cellular immune function of patients with hepatocellular cancer(HCC)in the medium and late stages before and after dual warhead drug(131I anti AFP pAb MMC or 131I anti mAb MMC) therapy. Methods The peripheral blood T cell subsets and NK cell activity were detected by APAAP staining and 51Cr release assay. Results T cell subsets(CD3+, CD4+),NK cell activity and ratio of CD4+/CD8+T cells had no significant changes in directed therapy group, but above immunological indexes declined significantly, the number of CD8+T cells increased markedly(P<0.05)in the chemo therapy group. Conclusion Dual warhead drug therapy has no effect on cellular immune function of HCC.
出处
《细胞与分子免疫学杂志》
CSCD
2000年第1期67-68,共2页
Chinese Journal of Cellular and Molecular Immunology
关键词
甲胎蛋白抗体
导向治疗
肝癌
T细胞亚群
NK细胞
anti AFP antibody
directed therapy
T cell subset hepatocellular
cancer
NK cell
MMC
